Journal
NEURODEGENERATIVE DISEASE MANAGEMENT
Volume 2, Issue 4, Pages 421-435Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/NMT.12.34
Keywords
-
Categories
Funding
- Huntington's Disease Society of America
- Cure Huntington's Disease Initiative Foundation, Inc.
- National Institute of Neurological Disorders and Stroke [R01 NS 37564]
Ask authors/readers for more resources
Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disorder that typically begins in middle adulthood. The neurodegenerative process that underlies HD, however, likely begins many years before clinical diagnosis. Since genetic testing can identify individuals that will develop HD during this preclinical period, clinical trials aiming to slow disease progression will likely focus on this phase of the illness in an effort to delay disease onset. How to best measure the efficacy of potential disease-modifying therapies in preclinical HD remains a complex challenge. This article will review the clinical and imaging measures that have been assessed as potential markers of disease progression in preclinical and early symptomatic HD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available